Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
73
resultados
Última actualización
27/12/2025 [07:18:00]
Resumen de: CN120712079A
The present invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition comprising killed intact bacteria intended for use in mammals and birds, said bacteria being wrapped with a cationic agent, in particular cationic nanoparticles.
Resumen de: WO2025255902A1
A primer and probe for detecting Salmonella pullorum, and a kit. The primer comprises SP-F and SP-R for detecting the target sequence of the Salmonella pullorum (SP) citE2 gene, and the probe is modified with a fluorescent reporter group and a fluorescent quenching group. By means of providing the primer pair of SP-F and SP-R, which pair specifically binds to the target sequence of the citE2 gene, and combining the primer pair with the probe, whic is used for specific recognition, the accurate and sensitive detection of Salmonella pullorum can be realized.
Resumen de: MX2025009214A
The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.
Resumen de: WO2024197078A2
Provided herein are compositions and methods for treating benign nervous system tumors, including schwannomas, using attenuated mutants of Salmonella typhimurium comprising a spiC deletion, and, optionally, one or more checkpoint inhibitors.
Resumen de: US2025377362A1
The invention provides analytical methods for identifying and quantifying complex glycoconjugate compositions, in particular for the analysis of a glycoconjugate in a sample comprising at least 4 glycoconjugates.
Resumen de: US2025375435A1
Disclosed herein are compositions and methods for treating a Salmonella infection. Disclosed herein are compositions and methods for inhibiting FraB in Salmonella. Disclosed herein are methods of increasing 6-phospho-fructose-aspartate within Salmonella bacteria.
Resumen de: WO2025246011A1
Provided are a method for enhancing the immunogenicity of a recombinant protein antigen and use thereof. The method comprises conjugating a polysaccharide with a recombinant protein antigen to form a nano-scale protein antigen. The polysaccharide is selected from sodium hyaluronate, chitosan, glucan, fucoidan, and sodium alginate. The recombinant protein antigen is a protein antigen derived from a bacterium. The bacterium belongs to the genus of Staphylococcus, Neisseria, Klebsiella, Escherichia, Clostridium, Salmonella, Shigella, Pseudomonas, Acinetobacter, Bordetella, Enterococcus, Haemophilus, Mycobacterium, or Streptococcus. The method not only improves the immunogenicity of the recombinant protein antigen, but also overcomes the defects of competitive immunoregulation and poor immune enhancement effects caused by bacterial capsular polysaccharide modification. The method also has the advantages of high clinical application value, simple starting material acquisition, low cost, good process stability, ease in scale expansion, high safety, and the like.
Resumen de: WO2024156739A1
The invention relates to a method for identifying a multi-parameter phenotype of microbiota. The method comprises (i) providing a sample comprising microbiota, (ii) labeling said microbiota with multiple labels, each of which binds a phenotypic parameter of said microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. The invention further relates to a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.
Resumen de: US2025360189A1
An immunogenic gel compositions for oral administration and methods of immunizing an animal the methods including administering to the animal a therapeutically effective amount of an immunogenic gel composition comprising an antigen of an animal pathogen and a gel composition for oral administration.
Resumen de: WO2025245361A1
The present invention relates to antigen presentation to CD8+ T cells. Systems and methods are provided for efficient presentation of diverse peptide antigens and induction of stimulatory and regulatory CD8+ T cell responses.
Resumen de: CN120202300A
The present invention relates to a DNA construct comprising: a gene encoding flagellin and a gene encoding an immunopotentiator (or adjuvant) protein. In order to achieve effective cancer treatment by selectively killing only cancer cells, the attenuated Salmonella strains of the present disclosure are designed to produce immunogenic substances in cancer tissue to induce a strong anti-cancer immune response to significantly inhibit tumor size in primary and metastatic cancers. Therefore, the strain can be advantageously used in a prophylactic or therapeutic composition for increasing survival rate.
Resumen de: WO2025238284A1
The present invention relates to a DNA construct that codes for a fusion protein comprising at least two enterohemorrhagic Escherichia coli antigens, for example, the antigens Int280, EspB, EspA, Stx2B, EspD, combinations or fragments thereof, vectors, fusion protein, immunisation methods and vaccines. The coded antigens can be fused Int280 and EspB of enterohemorrhagic Escherichia coli, forming a fusion protein with or without a connecting sequence between the two. The fused antigens can show the amino acid sequence SEQ ID No. 3 or SEQ ID No. 4 and are coded by the nucleotide sequence in SEQ ID No. 1 and SEQ ID No. 2. The construct can also comprise a signal sequence and a binding sequence for binding to the membrane of bacteria.
Resumen de: WO2025236040A1
Disclosed herein are solid lipid nanoparticles comprising a fatty acid esterified with polyethylene glycol. The polyethylene glycol is functionalised with an aptamer (i.e. targeting ligand). The nanoparticle may be loaded with an antibiotic or an antifungal, and a fluorescent compound. Also provided are their methods of preparation and their use in drug delivery and biosensing.
Resumen de: MX2025009500A
The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.
Resumen de: CN117838855A
The invention relates to a synthetic adhesive for limiting passage through mucus. Synthetic adhesives for reducing the proportion of targets that can traverse mucus and/or free cleavage are disclosed, as well as methods of using these synthetic adhesives to reduce mucosal penetration and/or free cleavage of targets.
Resumen de: CN120418260A
The present disclosure generally relates to improved methods for preparing glycoconjugates. The method includes conjugating a saccharide to a carrier protein using an acetoxyborohydride-containing reducing mixture prepared in situ.
Resumen de: WO2025233323A1
The invention relates to compositions of binding peptides, and individual binding peptides, capable of specific binding to either of two variants of OmpA occurring in pathogenic E. coli, and to methods employing these binding peptides for detection or isolation of pathogenic E. coli.
Resumen de: US2025345369A1
Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin and/or pagP−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd−, purI−, and msbB−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and/or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and/or are modified to induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.
Resumen de: MX2025009214A
The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.
Resumen de: CN120924562A
本发明公开了一种马链球菌和马流产沙门菌二联融合抗原，其核苷酸序列如SEQ ID NO.1所示。本发明将马流产沙门菌的FljB与马链球菌的SeM、EAG、GAPDH部分抗原串联重组在一起，不仅可以同时预防马链球菌和马流产沙门菌2种不同的马传染病，还增强了小鼠的体液免疫应答水平，利用该融合抗原免疫可获得抵抗马链球菌和马流产沙门菌的攻毒保护效果，高于单独抗原蛋白的免疫和灭活全菌的免疫，这解决了以往灭活疫苗免疫效率低和免疫繁琐的问题，有利于降低免疫的成本。
Resumen de: MX2025009214A
The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.
Resumen de: WO2025227308A1
A phage lyase with an amino acid sequence set forth in SEQ IN NO.2. The lyase can inhibit the growth of Staphylococcus, Escherichia, Klebsiella, and Salmonella bacteria, and can be used as an antibacterial substance in milk pollution control, belonging to the field of bioengineering. The phage lyase can be used for preparing an enzyme formulation alone or in a compounded manner to specifically inactivate bacteria such as Staphylococcus aureus, thereby providing an enzyme formulation source which is safe and free of toxic and side effects for controlling Staphylococcus aureus pollution in milk at present.
Resumen de: US2022125906A1
Compositions and methods for the treatment of benign nervous system tumors including schwannomas using attenuated Salmonella typhimurium and optionally one or more checkpoint inhibitors.
Resumen de: KR20230091594A
The present invention relates to a Salmonella mutant strain expressing anti-PD-L1 peptide, outer membrane vesicles thereof, and a pharmaceutical composition containing the same. The Salmonella mutant strain expresses the anti-PD-L1 peptide in an extracellular loop of an outer membrane protein A, and thus, the anti-PD-L1 peptide can be delivered stably and efficiently to the inside of the tumor due to the characteristics of Salmonella, and can exhibit an anti-tumor effect by inducing the activation of T cells through the formation of a bond with PD-1 of cancer cells, thereby using the Salmonella mutant strain or the membrane vesicles thereof for cancer treatment.
Nº publicación: MX2025009214A 03/11/2025
Solicitante:
THE UNIV COURT OF THE UNIV OF GLASGOW [GB]
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIV OF OXFORD [GB]
THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW,
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Resumen de: MX2025009214A
The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.
BOPI
Sede Electrónica
